Stock Ratings / Health Care / BCAX / dividends

OLMA (33) ABUS (22) LXRX (39) IMMX (33) ⌘ Pro Terminal →

Bicara Therapeutics Inc. (BCAX) Dividend Safety Gauge & 10-Year DRIP Compounder

Q: Is BCAX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Bicara Therapeutics Inc. (NASDAQ: BCAX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $9.73 (-0.31% 1D, market cap $643.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, BCAX ranks #478 in composite RQD confidence.

Q: How does BCAX compare to OLMA and ABUS in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BCAX carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, OLMA (Olema Pharmaceuticals Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -32.8%, cap $641.4M) and ABUS (Arbutus Biopharma Corporation) posts a E grade (22/100 RQD, P/E N/A, ROIC -35.0%, cap $656.0M). Among the 5-stock peer group, BCAX leads on earnings multiple (N/A) while LXRX leads on capital efficiency (-31.5% ROIC).

Q: What are the biggest fundamental strengths and SEC risk factors for BCAX?

Per BCAX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002023658), Bicara Therapeutics Inc. generated $0 in revenue, -$137.9M in net income, and -$107.1M in free cash flow against $431.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Q: Where is BCAX trading relative to its 50-day, 200-day, and 52-week technical levels?

BCAX last traded at $9.73 (-0.31% on volume of 3,197,807 shares), positioning the stock -50.71% below its 50-day simple moving average ($19.74) and -54.13% below its 200-day simple moving average ($21.21). Across its 52-week range of $8.36 to $30.99, BCAX sits at the 6.1% percentile with a 14-day RSI of 17.5 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($8.51 to $10.95).

Q: Does BCAX pay a dividend and is it safe?

Bicara Therapeutics Inc. (BCAX) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

$9.73 -0.31% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $9.71

Bicara Therapeutics Inc. (BCAX) carries a Roarable Rating of D (Sell) with 45/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows →

ROARABLE D • SELL / AVOID Cap $643.9M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

EXT / AFTER-HRS: $9.71 (-0.25%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 8/20 (D-) • 0% FCF Margin

Verify 90D Bucket Audit →

📊 Historical Track Record Warning: Scores below 50 (45/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.3% avg 90D alpha vs SPY • 29.0% hit rate).

Audit Bucket Track Record →

RQD QUANT TACHOMETERSELL / AVOID • D

3-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D- · Rk D+

Each axis scored 0–20

12M PRICE TARGET CONE-5.9% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BCAX)Realized 20D OHLCV Swing Band: ±12.5%

Deterministic 5-Pillar Attribution (45/100 Composite)

🔍 WHY BCAX SCORES 45/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag

▲ #1 Bullish Driver: Whale & Options Positioning+12/20 pts (27% of score)

20D Institutional Volume Accumulation (±12.5% realized swing band)

▲ #2 Bullish Driver: Macro Regime Fit+12/20 pts (27% of score)

FRED Regime × Technicals: 6% of 52W Range • RSI-14 at 17.5 (OVERSOLD (<32))

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current

Q1 (-3Q)

Grade C-$17.50-4.1% Next Q

Q2 (-2Q)

Grade C-$16.78+1.7% Next Q

Q3 (-1Q)

Grade D$17.07-43% Next Q

Current

Grade D$9.73-6.3% Hist 90D α

Trajectory: C- (53) → D (45)Full Audit →

⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a BCAX Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While BCAX currently carries a cautious 45/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($19.74) and Max Pain ($10.22) forces dealer call-delta covering toward $32.54.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BCAX• $2.4M Crowd Pool • Kalshi / Polymarket Composite

Contract: “BCAX Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”

YES 45%NO 55%Trade / Inspect Odds →

CASH DIVIDEND + BUYBACK YIELD

0.6% Total Yield

0% Cash ($0.00/yr) + 0.6% Buybacks

PAYOUT SAFETY SPEEDOMETER

74/100 • REINVESTING IN GROWTH + BUYBACKS

FREE CASH FLOW PAYOUT RATIO

0% (100% Reinvested)

Retains cash flow for R&D and share repurchases

INTERACTIVE DRIP & SHAREHOLDER-YIELD COMPOUNDER (5.5% EST. ANNUAL)

$10,000 Compounded Over 10 Years → $17,081

Est. Year-10 Shareholder Yield: $102/yr

Starting Investment: $10,000

Compounding Horizon: 10 Years

$10.6K

Yr 1

$11.1K

Yr 2

$11.7K

Yr 3

$12.4K

Yr 4

$13.1K

Yr 5

$13.8K

Yr 6

$14.5K

Yr 7

$15.3K

Yr 8

$16.2K

Yr 9

$17.1K

Yr 10

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BCAX)

✓Walkthrough of BCAX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

BCAX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -54.91%▼ SUPPORT BREAKDOWN

2026-10-30O $9.38H $9.73L $8.36C $9.73VOL 4.20M

RES: $17.62SUP: $15.26SMA50: $19.74SMA200: $21.21

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BCAX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 BCAX Butterfly Map → + Track BCAX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BCAX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for BCAX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for BCAX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BCAX)

Health Care Rank #478 of 1016 ⚔️ OLMA vs BCAX Full Matrix →

1. Head-to-Head Health Care Peer Comparison (BCAX vs. OLMA, ABUS, LXRX, IMMX)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Bicara Therapeutics Inc. (BCAX) ranks #478 by composite RQD confidence (45/100, grade D) and #413 by equity capitalization ($643.9M). Within this direct 5-issuer industry benchmark cohort, BCAX leads on earnings valuation at N/A trailing P/E, while LXRX leads on capital efficiency and profitability with -31.5% ROIC and 96.0% gross margin. BCAX currently leads its immediate peer cohort in composite quantitative strength at 45/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
BCAX ACTIVE Bicara Therapeutics Inc.	D	45/100	—	—	-35.0%	-0.31%	$643.9M	Benchmark Subject
OLMA Olema Pharmaceuticals Inc.	E	33/100	—	—	-32.8%	-2.14%	$641.4M	/olma-vs-bcax →
ABUS Arbutus Biopharma Corporation	E	22/100	—	—	-35.0%	-0.93%	$656.0M	/abus-vs-bcax →
LXRX Lexicon Pharmaceuticals Inc.	D-	39/100	—	96.0%	-31.5%	-0.34%	$658.5M	/lxrx-vs-bcax →
IMMX Immix Biopharma Inc.	E	33/100	—	—	-35.0%	-1.78%	$661.6M	/immx-vs-bcax →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0002023658

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Bicara Therapeutics Inc. (BCAX) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$137.9M, operating cash flow of -$106.8M, and free cash flow of -$107.1M (-43.2% YoY). On the balance sheet, BCAX closed FY2025 with $431.0M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$0	-$137.9M	-$106.8M	-$107.1M	$431.0M	—
FY2024 (FY)	2024-12-31	$0	-$68.0M	-$74.8M	-$74.8M	$510.0M	—
FY2023 (FY)	2023-12-31	$0	-$52.0M	-$45.6M	-$45.6M	—	—

3. BCAX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BCAX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Bicara Therapeutics Inc. (NASDAQ: BCAX) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 45/100 at a spot price of $9.73 (-0.31% 1D, market cap $643.9M). Pillar breakdown: Fundamental Cash Engine 8/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 12/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, BCAX ranks #478 in composite RQD confidence.

How does BCAX compare to OLMA and ABUS in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BCAX carries a Roarable D (45/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, OLMA (Olema Pharmaceuticals Inc.) holds a E grade (33/100 RQD, P/E N/A, ROIC -32.8%, cap $641.4M) and ABUS (Arbutus Biopharma Corporation) posts a E grade (22/100 RQD, P/E N/A, ROIC -35.0%, cap $656.0M). Among the 5-stock peer group, BCAX leads on earnings multiple (N/A) while LXRX leads on capital efficiency (-31.5% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BCAX?

Per BCAX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0002023658), Bicara Therapeutics Inc. generated $0 in revenue, -$137.9M in net income, and -$107.1M in free cash flow against $431.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BCAX trading relative to its 50-day, 200-day, and 52-week technical levels?

BCAX last traded at $9.73 (-0.31% on volume of 3,197,807 shares), positioning the stock -50.71% below its 50-day simple moving average ($19.74) and -54.13% below its 200-day simple moving average ($21.21). Across its 52-week range of $8.36 to $30.99, BCAX sits at the 6.1% percentile with a 14-day RSI of 17.5 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($8.51 to $10.95).

BCAX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Does BCAX pay a dividend and is it safe?

Bicara Therapeutics Inc. (BCAX) offers a 0% cash dividend yield ($0.00 annualized) and 0.6% total shareholder yield including buybacks. Roarable rates its payout coverage as REINVESTING IN GROWTH + BUYBACKS.

Direct Sub-Reports: BCAX RQD Cockpit BCAX 12M Forecast BCAX Earnings & Move BCAX Dividends & DRIP BCAX Insiders & 13F BCAX Whale Options BCAX Profit Sankey BCAX News & Why